Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
Pharmabiz
12h
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
14h
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
High-end brothel plea
Helene: How to help
'Harry Potter' star dies
Troops to leave some bases
Stadiums to serve as shelters
Promotes watch collection
Targeted Black residents?
World's oldest cheese found
Killer gets life sentence
50/50 ball ownership suit
Ending password-sharing
NIH finds misconduct
NC board removes 747K
More executives leave
Heads to US-Mexico border
Meta hit with privacy fine
Chinese submarine sank
Producing doc on Diddy
Urgent safety alert for 737s
Boxes to distribute Narcan
WI duplicate ballot flap
Fed inflation gauge cools
Fake Biden robocalls fine
Pleads not guilty
On Secret Service failures
US charges three Iranians
ISR targets Hezbollah HQ
Related topics
Bristol-Myers Squibb
2seventy
KarMMa-9
Feedback